[Form 4] LAVA Therapeutics NV Insider Trading Activity

Rhea-AI Filing Summary

Versant-related entities reported multiple sales of LAVA Therapeutics (LVTX) common stock on September 16-18, 2025. The filings show a series of dispositions: on 09/16/2025 two sell transactions of 307,707 and 192,293 shares at a weighted average price of $1.5332; on 09/17/2025 two sells of 362,806 and 226,726 shares at a weighted average price of $1.4892; and on 09/18/2025 two sells of 366,111 and 228,791 shares at a weighted average price of $1.4418. Following those transactions, Versant Venture Capital VI, L.P. held 3,099,450 shares (direct) and Versant Vantage I, L.P. held 988,387 shares (indirect) before/after as specified per line entries. Footnotes state the reported prices are weighted averages from multiple transactions within disclosed ranges and describe the related fund and GP ownership relationships.

Positive

• Full Section 16 disclosure across all reporting entities with signatures and explanatory footnotes
• Weighted-average prices and price ranges are disclosed and the filer offers to provide per-transaction details on request
• Clear GP/LP attribution language explains direct and indirect beneficial ownership

Negative

• Large aggregate insider sales occurred over three days (multiple transactions on 09/16, 09/17, 09/18/2025) which materially reduced reported holdings
• Selling at progressively lower weighted-average prices over the three days ($1.5332 to $1.4892 to $1.4418) as reported

Insights

Securities Analyst

TL;DR: Significant insider selling by affiliated venture funds across three days, quantitatively material to insider holdings.

The Form 4 shows coordinated dispositions by Versant-affiliated entities totaling over 1.6 million shares sold across 09/16-09/18/2025 at weighted average prices between $1.4418 and $1.5332. These filings explicitly identify direct and indirect holdings remaining after each sale and provide weighted-average price ranges. For investors, the clear, contemporaneous disclosure of multiple block sales by founding/venture stakeholders is a material liquidity event and could influence near-term supply dynamics in the stock. The filing also documents typical GP/LP attribution language in footnotes, clarifying beneficial ownership without attributing additional undisclosed shares.

Corporate Governance Expert

TL;DR: Proper Section 16 reporting by multiple related entities; ownership structure and disclaimers are clearly disclosed.

The submission includes the required signatures and footnotes explaining the GP/LP and affiliated-entity relationships and disclaims beneficial ownership beyond pecuniary interest where applicable. The Form 4 provides weighted-average pricing footnotes and offers to supply transaction-level detail on request, which aligns with SEC disclosure norms. From a governance and compliance perspective, the filing meets disclosure expectations for related-party dispositions and clarifies indirect ownership paths.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Versant Venture Capital VI, L.P.

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 1650

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		S		307,707	D	$1.5332(1)	3,099,450	D(2)
Common Stock	09/16/2025		S		192,293	D	$1.5332(1)	988,387	I	See Footnote(3)
Common Stock	09/17/2025		S		362,806	D	$1.4892(4)	2,736,644	D(2)
Common Stock	09/17/2025		S		226,726	D	$1.4892(4)	761,661	I	See Footnote(3)
Common Stock	09/18/2025		S		366,111	D	$1.4418(5)	2,370,533	D(2)
Common Stock	09/18/2025		S		228,791	D	$1.4418(5)	532,870	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Versant Venture Capital VI, L.P.

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 1650

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Versant Ventures VI GP, L.P.

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 1650

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Versant Ventures VI GP-GP, LLC

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 1650

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Versant Vantage I, L.P.

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 1650

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Versant Vantage I GP, L.P.

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 1650

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Versant Vantage I GP-GP, LLC

(Last) (First) (Middle)

ONE SANSOME STREET, SUITE 1650

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.50 to $1.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

2. These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

3. These shares are held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Each of VV I GP-GP and VV I GP may be deemed to share voting, investment and dispositive power over the shares held by VV I and disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.

4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.47 to $1.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

5. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.43 to $1.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

	Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	09/18/2025
	Versant Ventures VI GP, L.P., By: Versant Ventures VI GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	09/18/2025
	Versant Ventures VI GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer	09/18/2025
	Versant Vantage I, L.P. By: Versant Vantage I GP, L.P. Its: General Partner By: Versant Vantage I GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	09/18/2025
	Versant Vantage I GP, L.P., By: Versant Vantage I GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer	09/18/2025
	Versant Vantage I GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did the Form 4 report for LAVA Therapeutics (LVTX)?

The Form 4 reports multiple sales on 09/16/2025, 09/17/2025, and 09/18/2025 of common stock in blocks (e.g., 307,707; 192,293; 362,806; 226,726; 366,111; 228,791 shares) with weighted-average prices disclosed.

How many shares did Versant Venture Capital VI, L.P. hold after the reported transactions?

The filing lists 3,099,450 shares as held by Versant Venture Capital VI, L.P. (direct) following the reported transactions as shown on the Form 4 lines.

What prices were the shares sold at according to the Form 4?

Reported weighted-average prices were approximately $1.5332 (09/16), $1.4892 (09/17), and $1.4418 (09/18), with footnotes noting ranges for each day.

Do the filings explain the relationship between the reporting entities?

Yes. Footnotes explicitly describe GP/LP relationships and state that certain GP entities may be deemed to share voting, investment and dispositive power over the shares and disclaim beneficial ownership except to the extent of pecuniary interest.

Can I get per-transaction price breakdowns for the sales?

The filing states the reported prices are weighted averages and the Reporting Person undertakes to provide